Cited by 1,031Chemotherapy-induced cardiotoxicity and mitigationCardiac tumors and thrombiHIV-related health complications and treatments

The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations

Open access

Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A.R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M.G., Orecchia, R., de Azambuja, E., Zamorano, J.L., Krone, R., Iakobishvili, Z., Carver, J., Armenian, S., Ky, B., Cardinale, D., Cipolla, C.M., Dent, S., Jordan, K.·2020·Annals of Oncology

DOI 10.1016/j.annonc.2019.10.023PMC PMC8019325

Open this paper in CoChat — free account Open PDF

Abstract

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically through some deleterious effects of anticancer treatment on CV health. Anticancer therapies can cause a wide spectrum of short- and long-term cardiotoxic effects. An explosion of novel cancer therapies has revolutionised this field and dramatically altered cancer prognosis. Nevertheless, these new therapies have introduced unexpected CV complications beyond heart failure. Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment. This ESMO consensus article proposes to define CV toxicities related to cancer or its therapies and provide guidance regarding prevention, screening, monitoring and treatment of CV toxicity. The majority of anticancer therapies are associated with some CV toxicity, ranging from asymptomatic and transient to more clinically significant and long-lasting cardiac events. It is critical however, that concerns about potential CV damage resulting from anticancer therapies should be weighed against the potential benefits of cancer therapy, including benefits in overall survival. CV disease in patients with cancer is complex and treatment needs to be individualised. The scope of cardio-oncology is wide and includes prevention, detection, monitoring and treatment of CV toxicity related to cancer therapy, and also ensuring the safe development of future novel cancer treatments that minimise the impact on CV health. It is anticipated that the management strategies discussed herein will be suitable for the majority of patients. Nonetheless, the clinical judgment of physicians remains extremely important; hence, when using these best clinical practices to inform treatment options and decisions, practitioners should also consider the individual circumstances of their patients on a case-by-case basis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2019.10.023

Cites

221 of 221 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
Self-citation
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citation
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,432
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,137
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D. J., EIERMANN, W., Robert, N. J., Pieńkowski, T., Martín, M., Press, M. F., Mackey, J. R., Glaspy, J. A., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,833
American College of Sports Medicine Roundtable on Exercise Guidelines for Cancer Survivors
Schmitz, K. H., Courneya, K. S., Matthews, C., Demark-Wahnefried, W., GALVÃO, D. A., Pinto, B. M., IRWIN, M. L., WOLIN, K. Y., SEGAL, R. J., LUCIA, A., et al. (2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181e0c112 · Cited by 2,781
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Self-citation
Congestive heart failure in patients treated with doxorubicin
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,315
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Self-citation
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M. L., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T. B., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8776 · Cited by 2,234
Self-citation
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039 · cited 1×
“ribociclib).(57) Among the TKIs, for example, sunitinib, sorafenib, vandetanib, crizotinib, vemurafenib, dasatinib, lapatinib and nilotinib have product labellingwith standard or specific warnings to serious or life-threatening risks for QT interval prolongation.”
Background
Nutrition and physical activity guidelines for cancer survivors
Rock, C. L., Doyle, C., Demark‐Wahnefried, W., Meyerhardt, J., Courneya, K. S., Schwartz, A. L., Bandera, E. V., Hamilton, K. K., Grant, B., McCullough, M., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21142 · Cited by 1,995
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Self-citation
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Cella, D. F., Reeves, J. A., Hawkins, R. E., Guo, J., Nathan, P., Staehler, M. D., SOUZA, P. D., Merchan, J. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303989 · Cited by 1,928
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01683-7 · Cited by 1,909
Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer‐Crosbie, M., Gáname, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.07.012 · Cited by 1,802
Self-citation
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
Cardinale, D. M., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013777 · Cited by 1,741
Self-citation
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.037 · Cited by 1,608
Self-citation
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
Marty, M. E., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S. Y. T., Grimes, D., Antón, A., Lluch, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,602
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1215 · Cited by 1,565
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Pérez‐Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,397
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Armenian, S. H., Lacchetti, C., Barac, A., Carver, J. R., Constine, L. S., Denduluri, N., Dent, S. F., Douglas, P. S., Durand, J., Ewer, M. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5400 · Cited by 1,354
Self-citation
An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis
Speck, R. M., Courneya, K. S., Mâsse, L. C., Duval, S., & Schmitz, K. H. (2010) · Journal of Cancer Survivorship · doi:10.1007/s11764-009-0110-5 · Cited by 1,352
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Exposure to Low-Dose Ionizing Radiation from Medical Imaging Procedures
Fazel, R., Krumholz, H. M., Wang, Y., Ross, J. S., Chen, J., Ting, H. H., Shah, N. D., Nasir, K., Einstein, A. J., & Nallamothu, B. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901249 · Cited by 1,331
Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled Trial
Courneya, K. S., SEGAL, R. J., Mackey, J. R., Gelmon, K. A., Reid, R. D., Friedenreich, C. M., Ladha, A. B., Proulx, C., Vallance, J. K., Lane, K. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2024 · Cited by 1,182
Long-term Effects of a Lifestyle Intervention on Weight and Cardiovascular Risk Factors in Individuals With Type 2 Diabetes Mellitus: Four-Year Results of the Look AHEAD Trial
(2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.334 · Cited by 1,162
Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy
Thavendiranathan, P., Poulin, F., Lim, K. S., Plana, J. C., Woo, A., & Marwick, T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.073 · Cited by 1,116
Anthracycline-Induced Cardiomyopathy
Cardinale, D. M., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., Giacomi, G. D., Rubino, M., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.095 · Cited by 1,110
Self-citation
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkelä, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L. L. H., Woulfe, K. C., Pravda, E. A., Cassiola, F. M., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,097
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
Cardinale, D. M., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2006) · Circulation · doi:10.1161/circulationaha.106.635144 · Cited by 1,020
Self-citation
Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis
Protani, M. M., Coory, M. D., & Martin, J. H. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0990-0 · Cited by 985
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA · doi:10.1001/jama.1991.03470120074036 · Cited by 967
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
Cardinale, D. M., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F. A., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 951
Self-citation
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Himmelfarb, C. D., DePalma, S. M., Gidding, S. S., Jamerson, K., Jones, D. W., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.005 · Cited by 947
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942
Self-citation
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
Curigliano, G., Cardinale, D. M., Suter, T. M., Plataniotis, G., de Azambuja, E., Sandri, M. T., Criscitiello, C., Goldhirsch, A., Cipolla, C. M., & Roila, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds293 · Cited by 885
Self-citation
Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association
Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz‐Flores, S., Dent, S. F., Kondapalli, L., Ky, B., Okwuosa, T. M., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 883
Self-citation
Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab
Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Tan, T. C., Cohen, V., Banchs, J. A., Carver, J. R., Wiegers, S. E., et al. (2012) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.112.973321 · Cited by 813
Self-citation
Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials
Taylor, C. W., Correa, C. R., Duane, F. K., Aznar, M. C., Anderson, S., Bergh, J. C. S., Dodwell, D. J., Ewertz, M., Gray, R. G., Jagsi, R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.0722 · Cited by 802
Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31
Tan-Chiu, E., Yothers, G., Romond, E. H., Geyer, C. E., Ewer, M. S., Keefe, D. L., Shannon, R. P., Swain, S. M., Brown, A. M., Fehrenbacher, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4091 · Cited by 798
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
Curigliano, G., Cardinale, D. M., Dent, S. F., Criscitiello, C., Aseyev, O., Lenihan, D. J., & Cipolla, C. M. (2016) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21341 · Cited by 761
Self-citation
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
Smith, L. A., Cornelius, V. R., Plummer, C., Levitt, G., Verrill, M. W., Canney, P. A., & Jones, A. L. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-337 · Cited by 751
Modifiable Risk Factors and Major Cardiac Events Among Adult Survivors of Childhood Cancer
Armstrong, G. T., Oeffinger, K. C., Chen, Y., Kawashima, T. I., Yasui, Y., Leisenring, W. M., Stovall, M., Chow, E. J., Sklar, C. A., Mulrooney, D. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3205 · Cited by 737
Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment
Ewer, M. S., Vooletich, M. T., Durand, J., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.300 · Cited by 724
Self-citation
Reproducibility of Echocardiographic Techniques for Sequential Assessment of Left Ventricular Ejection Fraction and Volumes
Thavendiranathan, P., Grant, A. D., Negishi, T., Plana, J. C., Popović, Z., & Marwick, T. H. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.035 · Cited by 717
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Başar, E., Özdoğru, İ., Er, O. S., Çetinkaya, Y., Doğan, A., Oğuzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 708
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
Gulati, G., Heck, S. L., Ree, A. H., Hoffmann, P., Schulz‐Menger, J., Fagerland, M. W., Gravdehaug, B., von Knobelsdorff‐Brenkenhoff, F., Bratland, Å., Storås, T. H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw022 · Cited by 702
Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients
Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Cohen, V., Gosavi, S., Carver, J. R., Wiegers, S. E., Martin, R. P., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.01.006 · Cited by 680
Self-citation
Weight, Weight Gain, and Survival After Breast Cancer Diagnosis
Kroenke, C. H., Chen, W. Y., Rosner, B., & Holmes, M. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.079 · Cited by 670
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S. P., York, M., Spicer, D. V., Jones, S. E., Wadler, S., Desai, A. V., Vogel, C. L., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 661
Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men Undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled Trial
Galvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., & Newton, R. U. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2488 · Cited by 657
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Moslehi, J. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1100265 · Cited by 652
Self-citation
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
Cardinale, D. M., Colombo, A., Torrisi, R., Sandri, M. T., Civelli, M., Salvatici, M., Lamantia, G., Colombo, N., Cortinovis, S., Dessanai, M. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3615 · Cited by 647
Self-citation
Valvular Dysfunction and Carotid, Subclavian, and Coronary Artery Disease in Survivors of Hodgkin Lymphoma Treated With Radiation Therapy
Hull, M. C. (2003) · JAMA · doi:10.1001/jama.290.21.2831 · Cited by 645
Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients
Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 637
Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies
Bosch, X., Rovira, M., Sitges, M., Domènech, A., Ortiz-Pérez, J. T., de Caralt, T. M., Morales‐Ruiz, M., Perea, R. J., Monzó, M., & Esteve, J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.072 · Cited by 632
The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia
Lipshultz, S. E., Rifai, N., Dalton, V., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 620
Weight Loss in Breast Cancer Patient Management
Chlebowski, R. T., Aiello, E. J., & McTiernan, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.4.1128 · Cited by 618
Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojić, M., Schukro, C., Ruhsam, M., Hejna, M., & Schmidinger, H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6331 · Cited by 611
Immune checkpoint inhibitors and cardiovascular toxicity
Lyon, A. R., Yousaf, N., Battisti, N. M. L., Moslehi, J., & Larkin, J. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30457-1 · Cited by 575
Self-citation
Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab
Ky, B., Putt, M. E., Sawaya, H., French, B. C., Januzzi, J. L., Sebag, I. A., Plana, J. C., Cohen, V., Banchs, J. A., Carver, J. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.061 · Cited by 567
Self-citation
Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
Suter, T. M., Procter, M. J., van Veldhuisen, D. J., Muscholl, M. W., Bergh, J. C. S., Carlomagno, C., Perren, T. J., Passalacqua, R., Bighin, C., Klijn, J. G. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1611 · Cited by 565
Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study
Armenian, S. H., Xu, L., Ky, B., Sun, C., Farol, L. T., Pal, S. K., Douglas, P. S., Bhatia, S., & Chao, C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0409 · Cited by 562
Self-citation
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003917.pub4 · Cited by 553
Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification
Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L. K., Kaptain, S., Bach, A. M., Panageas, K. S., Arroyo, C. D., Valero, V., Currie, V. E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 546
Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial
Perez, E. A., Suman, V. J., Davidson, N. E., Sledge, G. W., Kaufman, P. A., Hudis, C. A., Martino, S., Gralow, J. R., Dakhil, S. R., Ingle, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5467 · Cited by 536
Myocardial Strain Measurement With 2-Dimensional Speckle-Tracking Echocardiography
Marwick, T. H., Leano, R., Brown, J. K., Sun, J.-P., Hoffmann, R., Lysyansky, P., Becker, M., & Thomas, J. D. (2009) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2007.12.007 · Cited by 530
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity
Ávila, M. S., Ayub‐Ferreira, S. M., Wanderley, M. R. D. B., Cruz, F. D. D., Brandão, S. M. G., Rigaud, V. O. C., dos Santos, M. H. H., Hajjar, L. A., Filho, R. K., Hoff, P. M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.049 · Cited by 510
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy
Schwartz, R. G., Mckenzie, W., Alexander, J. S., Sager, P. T., D'Souza, A. W., Manatunga, A. K., Schwartz, P. E., Berger, H. J., Setaro, J. F., Surkin, L. A., et al. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90212-9 · Cited by 509
Long-term Effects of a Lifestyle Intervention on Weight and Cardiovascular Risk Factors in Individuals With Type 2 Diabetes Mellitus: Four-Year Results of the Look AHEAD Trial
Roizen, M. F. (2011) · Yearbook of Anesthesiology and Pain Management · doi:10.1016/j.yane.2011.01.029 · Cited by 487
The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Treated With Adjuvant Trastuzumab Therapy
Fallah‐Rad, N., Walker, J. R., Wassef, A., Lytwyn, M., Bohonis, S., Fang, T., Tian, G., Kirkpatrick, I. D. C., Singal, P. K., Krahn, M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.063 · Cited by 485
Expert Consensus for Multi-Modality Imaging Evaluation of Cardiovascular Complications of Radiotherapy in Adults: A Report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography
Lancellotti, P., Nkomo, V. T., Badano, L. P., Bergler-Klein, J. K., Bogaert, J. G., Davin, L., Cosyns, B., Coucke, P. A., Dulgheru, R., Edvardsen, T., et al. (2013) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2013.07.005 · Cited by 484
Self-citation
Cardiovascular Disease Mortality Among Breast Cancer Survivors
Bradshaw, P. T., Stevens, J., Khankari, N. K., Teitelbaum, S. L., Neugut, A. I., & Gammon, M. D. (2015) · Epidemiology · doi:10.1097/ede.0000000000000394 · Cited by 457
Independent and Incremental Value of Deformation Indices for Prediction of Trastuzumab-Induced Cardiotoxicity
Negishi, K., Negishi, T., Hare, J., Haluska, B. A., Plana, J. C., & Marwick, T. H. (2013) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2013.02.008 · Cited by 455
Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon Cancer
Meyerhardt, J. A., Niedzwiecki, D., Hollis, D. R., Saltz, L. B., Hu, F. B., Mayer, R. J., Nelson, H., Whittom, R., Hantel, A., Thomas, J. P., et al. (2007) · JAMA · doi:10.1001/jama.298.7.754 · Cited by 444
Performance of 3-Dimensional Echocardiography in Measuring Left Ventricular Volumes and Ejection Fraction
Dorosz, J. L., Lezotte, D. C., Weitzenkamp, D. A., Allen, L. A., & Salcedo, E. E. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.037 · Cited by 432
Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
Maitland, M. L., Bakris, G. L., Black, H. R., Chen, H. X., Durand, J., Elliott, W. J., Ivy, S. P., Leier, C. V., Lindenfeld, J. M., Liu, G., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq091 · Cited by 416
Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101–Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity
Pituskin, E., Mackey, J. R., Koshman, S. L., Jassal, D. S., Pitz, M. W., Haykowsky, M. J., Pagano, J. J., Chow, K., Thompson, R. B., Vos, L. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.7830 · Cited by 411
Cardiovascular Side Effects of Cancer Therapies: A Position Statement from the Heart Failure Association of the European Society of Cardiology
Eschenhagen, T., Force, T. L., Ewer, M. S., Keulenaer, G. W. D., Suter, T. M., Anker, S. D., Avkiran, M., de Azambuja, E., Balligand, J., Brutsaert, D. L., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq213 · Cited by 410
Cardiac Complications of Thoracic Irradiation
Jaworski, C., Mariani, J. A., Wheeler, G., & Kaye, D. M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.090 · Cited by 395
Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function
Otterstad, J. E., Froeland, G., Sutton, M. S. J., & Holme, I. (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015273 · Cited by 393
Asymptomatic cardiac disease following mediastinal irradiation
Heidenreich, P. A., Hancock, S., Lee, B. K., Mariscal, C. S., & Schnittger, I. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00759-9 · Cited by 393
Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility
Telli, M. L., Hunt, S. A., Carlson, R. W., & Guardino, A. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0106 · Cited by 388
Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury
Lipshultz, S. E., Rifai, N., Sallan, S. E., Lipsitz, S. R., Dalton, V., Sacks, D. B., & Ottlinger, M. E. (1997) · Circulation · doi:10.1161/01.cir.96.8.2641 · Cited by 383
Cancer survival: global surveillance will stimulate health policy and improve equity
Coleman, M. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62225-4 · Cited by 370
Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non–Small-Cell Lung Cancer
Dess, R. T., Sun, Y., Matuszak, M. M., Sun, G. Y., Soni, P., Bazzi, L. A., Murthy, V. L., Hearn, J. W. D., Kong, F., Kalemkerian, G. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6142 · Cited by 370
Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience
Guarneri, V., Lenihan, D. J., Valero, V., Durand, J., Broglio, K. R., Hess, K. R., Michaud, L. B., Gonzalez-Angulo, A. M., Hortobágyi, G. N., & Esteva, F. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9551 · Cited by 364
Self-citation
Functional monitoring of anthracycline cardiotoxicity:a prospective, blinded, long-term observational study of outcome in 120 patients
Jensen, B. V., Skovsgaard, T., & Nielsen, S. L. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf132 · Cited by 340
Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality
Wright, M. E., Chang, S., Schatzkin, A. G., Albanes, D., Kipnis, V., Mouw, T., Hurwitz, P. E., Hollenbeck, A. R., & Leitzmann, M. F. (2007) · Cancer · doi:10.1002/cncr.22443 · Cited by 336
The Burden of Disease and the Changing Task of Medicine
Jones, D. S., Podolsky, S. H., & Greene, J. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1113569 · Cited by 332
Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA
Mayer, D. K., Nasso, S. F., & Earp, J. A. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30573-3 · Cited by 330
Effect of Statin Therapy on the Risk for Incident Heart Failure in Patients With Breast Cancer Receiving Anthracycline Chemotherapy
Seicean, S., Seicean, A., Plana, J. C., Budd, G. T., & Marwick, T. H. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.067 · Cited by 325
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Bird, B., & Swain, S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1033 · Cited by 314
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
Cardinale, D. M., Sandri, M. T., Martinoni, A., Borghini, E., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Fiorentini, C., & Cipolla, C. M. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf170 · Cited by 313
Self-citation
Cardio-Oncology Services: rationale, organization, and implementation
Lancellotti, P., Suter, T. M., López‐Fernández, T., Galderisi, M., Lyon, A. R., van der Meer, P., Solal, A. C., Zamorano, J. L., Jérusalem, G., Moonen, M. L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy453 · Cited by 313
Self-citation
Long-Term Enalapril Therapy for Left Ventricular Dysfunction in Doxorubicin-Treated Survivors of Childhood Cancer
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Simbre, V. C., Shaikh, S., Mone, S. M., Gelber, R. D., & Colan, S. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.102 · Cited by 308
Enalapril to Prevent Cardiac Function Decline in Long-Term Survivors of Pediatric Cancer Exposed to Anthracyclines
Silber, J. H., Cnaan, A., Clark, B. J., Paridon, S. M., Chin, A. J., Rychik, J. R., Hogarty, A. N., Cohen, M. I., Barber, G., Rutkowski, M. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.022 · Cited by 300
Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
Choueiri, T. K., Mayer, E. L., Je, Y., Rosenberg, J. E., Nguyen, P. L., Azzi, G., Joaquim Bellmunt, B., Burstein, H. J., & Schutz, F. A. B. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9129 · Cited by 296
Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer
Guglin, M. E., Krischer, J. P., Tamura, R., Fink, A., Bello-Matricaria, L., McCaskill‐Stevens, W., & Münster, P. N. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.495 · Cited by 291
Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography
Hoffmann, R., von Bardeleben, S., ten Cate, F. J., Borges, A. C., Kasprzak, J. D., Firschke, C., Lafitte, S., Al‐Saadi, N., Kuntz‐Hehner, S., Engelhardt, M. F., et al. (2004) · European Heart Journal · doi:10.1093/eurheartj/ehi083 · Cited by 284
Updated evidence in support of diet and exercise interventions in cancer survivors
Pekmezi, D., & Demark‐Wahnefried, W. (2010) · Acta Oncologica · doi:10.3109/0284186x.2010.529822 · Cited by 279
Probabilities of Death From Breast Cancer and Other Causes Among Female Breast Cancer Patients
Schairer, C., Mink, P. J., Carroll, L. E., & Devesa, S. S. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh253 · Cited by 275
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
Swain, S. M., Whaley, F. S., Gerber, M. C., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1333 · Cited by 268
Protective Effects of Spironolactone Against Anthracycline-Induced Cardiomyopathy
Akpek, M., Özdoğru, İ., Şahin, Ö., İnanç, M., Doğan, A., Yazıcı, C., Berk, V., Karaca, H., Kalay, N., Oğuzhan, A., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.196 · Cited by 262
Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803
Meyerhardt, J. A., Niedzwiecki, D., Hollis, D. R., Saltz, L. B., Mayer, R. J., Nelson, H., Whittom, R., Hantel, A., Thomas, J., & Fuchs, C. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6687 · Cited by 259
Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis
Abdel-Qadir, H. M., Ethier, J.-L., Lee, D. S., Thavendiranathan, P., & Amir, E. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.002 · Cited by 256
Efficiency of Atorvastatin in the Protection of Anthracycline-Induced Cardiomyopathy
Acar, Z., Kale, A., Turgut, M., Demircan, S., Durna, K., Demır, S., Meriç, M., & Ağaç, M. T. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.025 · Cited by 254
Heart failure associated with sunitinib malate
Khakoo, A. Y., Kassiotis, C., Tannir, N. M., Plana, J. C., Halushka, M. K., Bickford, C. L., Trent, J., Champion, J. C., Durand, J., & Lenihan, D. J. (2008) · Cancer · doi:10.1002/cncr.23460 · Cited by 251
Self-citation
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial
Cardinale, D. M., Ciceri, F., Latini, R., Franzosi, M. G., Sandri, M. T., Civelli, M., Cucchi, G., Menatti, E., Mangiavacchi, M., Cavina, R., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.005 · Cited by 248
Self-citation
Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection
Negishi, K., Negishi, T., Haluska, B. A., Hare, J., Plana, J. C., & Marwick, T. H. (2013) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jet159 · Cited by 246
Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein Kinase
Kerkelä, R., Woulfe, K. C., Durand, J., Vagnozzi, R. J., Kramer, D., Chu, T. F., Beahm, C., Chen, M. H., & Force, T. L. (2009) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2008.00090.x · Cited by 245
Impact of Comorbidity on Chemotherapy Use and Outcomes in Solid Tumors: A Systematic Review
Lee, L., Cheung, W. Y., Atkinson, E., & Krzyzanowska, M. K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.3049 · Cited by 237
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy
Virani, S., Dent, S. F., Brezden‐Masley, C., Clarke, B. A., Davis, M. K., Jassal, D. S., Johnson, C. B., Lemieux, J., Paterson, D. I., Sebag, I. A., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.02.078 · Cited by 236
Self-citation
Cardiovascular Toxicities of Immune Checkpoint Inhibitors
Ball, S., Ghosh, R. K., Wongsaengsak, S., Bandyopadhyay, D., Ghosh, G. C., Aronow, W. S., Fonarow, G. C., Lenihan, D. J., & Bhatt, D. L. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.079 · Cited by 231
Self-citation
Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy
Mulrooney, D. A., Armstrong, G. T., Huang, S., Ness, K. K., Ehrhardt, M. J., Joshi, V. M., Plana, J. C., Soliman, E. Z., Green, D. M., Srivastava, D. K., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-0424 · Cited by 230
Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease
Armenian, S. H., Sun, C., Vase, T., Ness, K. K., Blum, E., Francisco, L., Venkataraman, K., Samoa, R. A., Wong, F. L., Forman, S. J., et al. (2012) · Blood · doi:10.1182/blood-2012-06-437178 · Cited by 217
Self-citation
Correlation Between Serum Levels of Cardiac Troponin-T and the Severity of the Chronic Cardiomyopathy Induced by Doxorubicin
Herman, E. H., Zhang, J., Lipshultz, S. E., Rifai, N., Chadwick, D. P., Takeda, K., Yu, Z., & Ferrans, V. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2237 · Cited by 208
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies
Li, W., Croce, K., Steensma, D. P., McDermott, D. F., Ben‐Yehuda, O., & Moslehi, J. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.025 · Cited by 208
Self-citation
Changes in Left Ventricular Longitudinal Strain with Anthracycline Chemotherapy in Adolescents Precede Subsequent Decreased Left Ventricular Ejection Fraction
Poterucha, J. T., Kutty, S., Lindquist, R. K., Li, L., & Eidem, B. W. (2012) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2012.04.007 · Cited by 208
The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients
Hall, P. S., Harshman, L. C., Srinivas, S., & Witteles, R. M. (2013) · JACC Heart Failure · doi:10.1016/j.jchf.2012.09.001 · Cited by 208
Self-citation
Left Ventricular Ejection Fraction and Cardiotoxicity: Is Our Ear Really to the Ground?
Ewer, M. S., & Lenihan, D. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8742 · Cited by 207
Self-citation
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway
Hamnvik, O. R., Choueiri, T. K., Turchin, A., McKay, R. R., Goyal, L., Davis, M. E., Kaymakcalan, M. D., & Williams, J. S. (2014) · Cancer · doi:10.1002/cncr.28972 · Cited by 204
Dietary Patterns and Breast Cancer Recurrence and Survival Among Women With Early-Stage Breast Cancer
Kwan, M. L., Weltzien, E. K., Kushi, L. H., Castillo, A., Slattery, M. L., & Caan, B. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4035 · Cited by 204
Dietary Patterns and Survival After Breast Cancer Diagnosis
Kroenke, C. H., Fung, T. T., Hu, F. B., & Holmes, M. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0198 · Cited by 200
Immune Checkpoint Inhibitor–Associated Myositis
Anquetil, C., Salem, J., Lebrun‐Vignes, B., Johnson, D. B., Mammen, A. L., Stenzel, W., Léonard-Louis, S., Benvéniste, O., Moslehi, J. J., & Allenbach, Y. (2018) · Circulation · doi:10.1161/circulationaha.118.035898 · Cited by 200
Self-citation
Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease
Groarke, J. D., Nguyen, P. L., Nohria, A., Ferrari, R., Cheng, S. C., & Moslehi, J. J. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht114 · Cited by 198
Self-citation
Role of Three-Dimensional Echocardiography in Breast Cancer: Comparison With Two-Dimensional Echocardiography, Multiple-Gated Acquisition Scans, and Cardiac Magnetic Resonance Imaging
Walker, J. R., Bhullar, N., Fallah‐Rad, N., Lytwyn, M., Golian, M., Fang, T., Summers, A. R., Singal, P. K., Barač, I., Kirkpatrick, I. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7294 · Cited by 198
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma
Cornell, R. F., Ky, B., Weiss, B. M., Dahm, C. N., Gupta, D. K., Du, L., Carver, J. R., Cohen, A. D., Engelhardt, B. G., Garfall, A. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00231 · Cited by 198
Self-citation
Strain Rate Imaging Detects Early Cardiac Effects of Pegylated Liposomal Doxorubicin as Adjuvant Therapy in Elderly Patients with Breast Cancer
Jurcut, R. O., Wildiers, H. P. M. W., Gáname, J., D’hooge, J., Backer, J. F. A. D., Denys, H. G., Paridaens, R., Rademakers, F. E., & Voigt, J. (2008) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2008.10.005 · Cited by 185
Incidence and Risk of Congestive Heart Failure in Patients With Renal and Nonrenal Cell Carcinoma Treated With Sunitinib
Richards, C. J., Je, Y., Schutz, F. A. B., Heng, D. Y. C., Dallabrida, S. M., Moslehi, J. J., & Choueiri, T. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4309 · Cited by 182
Self-citation
Late Cardiac Effects of Cancer Treatment
Lenihan, D. J., & Cardinale, D. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2938 · Cited by 181
Self-citation
Noninvasive quantification of regional myocardial function using Doppler-derived velocity, displacement, strain rate, and strain in healthy volunteers: effects of aging
Sun, J. P., Popović, Z., Greenberg, N. L., Xu, X., Asher, C. R., Stewart, W. J., & Thomas, J. D. (2004) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2003.10.001 · Cited by 177
Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment
Maitland, M. L., Kasza, K., Karrison, T. G., Moshier, K., Sit, L., Black, H. R., Undevia, S. D., Stadler, W. M., Elliott, W. J., & Ratain, M. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0058 · Cited by 176
Detailed Echocardiographic Phenotyping in Breast Cancer Patients
Narayan, H. K., Finkelman, B. S., French, B. C., Plappert, T. A., Hyman, D. M., Smith, A. M., Margulies, K. B., & Ky, B. (2017) · Circulation · doi:10.1161/circulationaha.116.023463 · Cited by 174
Self-citation
Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)
Shah, R. R., Morganroth, J., & Shah, D. R. (2013) · Drug Safety · doi:10.1007/s40264-013-0047-5 · Cited by 172
Role of Biomarkers in Chemotherapy-Induced Cardiotoxicity
Cardinale, D. M., & Sandri, M. T. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.04.002 · Cited by 167
Self-citation
cTnT can be a useful marker for early detection of anthracycline cardiotoxicity
Kılıçkap, S., Barışta, İ., Akgul, E., Aytemir, K., Aksöyek, S., Aksoy, S., Celik, I., Kes, S., & Tekuzman, G. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi152 · Cited by 166
Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy
Zardavas, D., Suter, T. M., van Veldhuisen, D. J., Steinseifer, J., Noé, J., Lauer, S., Al-Sakaff, N. J. A., Piccart, M. J., & de Azambuja, E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7916 · Cited by 165
Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients
Nousiainen, T., Jantunen, E., Vanninen, E. J., & Hartikainen, J. E. K. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600346 · Cited by 164
Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer
Bhatia, N., dos Santos, M. H. H., Jones, L. W., Beckman, J. A., Penson, D. F., Morgans, A., & Moslehi, J. J. (2016) · Circulation · doi:10.1161/circulationaha.115.012519 · Cited by 156
Self-citation
Acute Cardiac Functional and Morphological Changes After Anthracycline Infusions in Children
Gáname, J., Claus, P., Eyskens, B., Uyttebroeck, A., Renard, M., D’hooge, J., Gewillig, M. H. M. L., Bijnens, B. H., Sutherland, G. R., & Mertens, L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.063 · Cited by 155
Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era
Mitani, I., Jain, D., Joska, T. M., Burtness, B. A., & Zaret, B. L. (2003) · Journal of Nuclear Cardiology · doi:10.1067/mnc.2003.7 · Cited by 140
CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children’s Oncology Group Genome-Wide Association Study
Wang, X., Sun, C., Quiñones‐Lombraña, A., Singh, P., Landier, W., Hageman, L., Mather, M. A., Rotter, J. I., Taylor, K. D., Chen, Y. I., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4550 · Cited by 137
Self-citation
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P. A., Bello, C. M., Benitez, C. M., Bernat, K., Bierman, P. J., Blum, K. A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0064 · Cited by 137
Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies
Yoon, G., Telli, M. L., Kao, D. P., Matsuda, K. Y., Carlson, R. W., & Witteles, R. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.023 · Cited by 135
Self-citation
Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma
McKay, R. R., Rodriguez, G. E., Lin, X., Kaymakcalan, M. D., Hamnvik, O. R., Sabbisetti, V. S., Bhatt, R. S., Simantov, R., & Choueiri, T. K. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2332 · Cited by 133
Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
Perez, E. A., Suman, V. J., Davidson, N. E., Kaufman, P. A., Martino, S., Dakhil, S. R., Ingle, J. N., Rodeheffer, R. J., Gersh, B. J., & Jaffe, A. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.516 · Cited by 131
Overview and Management of Cardiac Adverse Events Associated With Tyrosine Kinase Inhibitors
Lenihan, D. J., & Kowey, P. R. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0466 · Cited by 122
Self-citation
Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?
Vaklavas, C., Lenihan, D. J., Kurzrock, R., & Tsimberidou, A. M. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0252 · Cited by 119
Self-citation
Influence of Conventional Cardiovascular Risk Factors and Lifestyle Characteristics on Cardiovascular Disease After Hematopoietic Cell Transplantation
Chow, E. J., Baker, K. S., Lee, S. J., Flowers, M. E. D., Cushing‐Haugen, K. L., Inamoto, Y., Khera, N., Leisenring, W. M., Syrjala, K. L., & Martin, P. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.6582 · Cited by 117
The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice
Howlett, J. G., Chan, M. C. Y., Ezekowitz, J. A., Harkness, K. I., Heckman, G. A., Kouz, S., Leblanc, M.-H., Moe, G. W. P. L., O’Meara, E., Abrams, H. B., et al. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.06.019 · Cited by 116
Incidence and risk of hypertension with a novel multi‐targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta‐analysis
Qi, W., He, A., Shen, Z., & Yao, Y. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12149 · Cited by 114
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors
Steingart, R. M., Bakris, G. L., Chen, H. X., Chen, M., Force, T. L., Ivy, S. P., Leier, C. V., Liu, G., Lenihan, D. J., Lindenfeld, J. M., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.10.018 · Cited by 114
Self-citation
Cost-Effectiveness of the Children's Oncology Group Long-Term Follow-up Screening Guidelines for Childhood Cancer Survivors at Risk for Treatment-Related Heart Failure
Wong, F. L., Bhatia, R., Landier, W., Francisco, L., Leisenring, W. M., Hudson, M. M., Armstrong, G. T., Mertens, A. C., Stovall, M., Robison, L. L., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2498 · Cited by 113
Self-citation
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
Neilan, T. G., Rothenberg, M. L., Amiri‐Kordestani, L., Sullivan, R. J., Steingart, R. M., Gregory, W. W., Hariharan, S., Hammad, T. A., Lindenfeld, J. M., Murphy, M. J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0157 · Cited by 107
Self-citation
BNP Predicts Chemotherapy-Related Cardiotoxicity and Death: Comparison with Gated Equilibrium Radionuclide Ventriculography
Skovgaard, D. C., Hasbak, P., & Kjær, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096736 · Cited by 105
Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist
Mornoş, C., & Petrescu, L. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2012-0398 · Cited by 96
Abnormal Exercise Response in Long-Term Survivors of Hodgkin Lymphoma Treated With Thoracic Irradiation
Groarke, J. D., Tanguturi, V. K., Hainer, J. M., Klein, J., Moslehi, J. J., Ng, A. K., Forman, D. E., Carli, M. F. D., & Nohria, A. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.11.035 · Cited by 94
Self-citation
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events
Ewer, M. S., Suter, T. M., Lenihan, D. J., Niculescu, L., Breazna, A., Demetri, G. D., & Motzer, R. J. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.05.013 · Cited by 93
Self-citation
Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis
Qi, W., Lin, F., Sun, Y., Tang, L., He, A., Yao, Y., & Shen, Z. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2025-5 · Cited by 90
Cirrhosis and hepatoma occurring at Boston city hospital (1917-1968)
Purtilo, D. T., & Gottlieb, L. S. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2 · Cited by 90
Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta‐analysis of 36 clinical trials
Qi, W., Shen, Z., Tang, L., & Yao, Y. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12387 · Cited by 88
The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study
Lenihan, D. J., Stevens, P. L., Massey, M., Plana, J. C., Araujo, D. M., Fanale, M. A., Fayad, L., Fisch, M. J., & Yeh, E. T. H. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2016.04.003 · Cited by 88
Self-citation
Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
Ganatra, S., Nohria, A., Shah, S. P., Groarke, J. D., Sharma, A. K., Venesy, D. M., Patten, R. D., Gunturu, K. S., Zarwan, C., Neilan, T. G., et al. (2019) · Cardio-Oncology · doi:10.1186/s40959-019-0036-7 · Cited by 88
Self-citation
The Compelling Need for a Cardiology and Oncology Partnership and the Birth of the International CardiOncology Society
Lenihan, D. J., Cardinale, D. M., & Cipolla, C. M. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.06.002 · Cited by 82
Self-citation
Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy
Curwen, J., Musgrove, H. L., Kendrew, J., Richmond, G. H. P., Ogilvie, D., & Wedge, S. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4783 · Cited by 81
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour, L., Bramwell, V., & Moran, L. A. (1999) · PubMed · Cited by 78
Cardiac Magnetic Resonance Imaging Findings in 20-year Survivors of Mediastinal Radiotherapy for Hodgkin's Disease
Machann, W., Beer, M., Breunig, M., Störk, S., Angermann, C., Seufert, I., Schwab, F. J., Kölbl, O., Flentje, M. P., & Vordermark, D. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.12.054 · Cited by 78
Preparing the Cardiovascular Workforce to Care for Oncology Patients
Hayek, S. S., Ganatra, S., Lenneman, C., Scherrer‐Crosbie, M., Leja, M. J., Lenihan, D. J., Yang, E. H., Ryan, T. D., Liu, J., Carver, J. R., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.041 · Cited by 77
Self-citation
Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma
Narayan, V., O’Keefe, S. J., Haas, N. B., Wang, L., Puzanov, I. J., Putt, M., Catino, A., Fang, J. C.-T., Agarwal, N., Hyman, D. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2869 · Cited by 76
Self-citation
The Effects of Obesity and Obesity-Related Conditions on Colorectal Cancer Prognosis
Siegel, E. M., Ulrich, C. M., Poole, E. M., Holmes, R. S., Jacobsen, P. B., & Shibata, D. (2010) · Cancer Control · doi:10.1177/107327481001700107 · Cited by 73
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H., & Kremer, L. C. M. (2005) · doi:10.1002/14651858.cd003917.pub2 · Cited by 70
Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy
Motoki, H., Koyama, J., Nakazawa, H., Aizawa, K., Kasai, H., Izawa, A., Tomita, T., Miyashita, Y., Kumazaki, S., Takahashi, M., et al. (2011) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ejechocard/jer172 · Cited by 66
Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty
Lenihan, D. J., Hartlage, G. R., DeCara, J. M., Blaes, A. H., Finet, J. E., Lyon, A. R., Cornell, R. F., Moslehi, J. J., Oliveira, G. H., Murtagh, G., et al. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2016.03.012 · Cited by 63
Self-citation
Energetics in Colorectal and Prostate Cancer
Meyerhardt, J. A., Ma, J., & Courneya, K. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.8797 · Cited by 62
Statins, risk assessment, and the new American prevention guidelines
Lloyd‐Jones, D. M., Goff, D. C., & Stone, N. J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62348-x · Cited by 61
Cancer Therapy-Induced Left Ventricular Dysfunction: Interventions and Prognosis
Thakur, A., & Witteles, R. M. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2013.12.018 · Cited by 59
Self-citation
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer
Untch, M., Eidtmann, H., du Bois, A., Meerpohl, H. G., Thomssen, C., Ebert, A. D., Harbeck, N., Jackisch, C., Heilmann, V., Emons, G., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.011 · Cited by 59
Early Myocardial Strain Changes During Potentially Cardiotoxic Chemotherapy May Occur as a Result of Reductions in Left Ventricular End-Diastolic Volume
Jordan, J. H., Sukpraphrute, B., Meléndez, G. C., Jolly, M., D’Agostino, R. B., & Hundley, W. G. (2017) · Circulation · doi:10.1161/circulationaha.117.027930 · Cited by 59
Dexrazoxane Significantly Reduces Anthracycline-induced Cardiotoxicity in Pediatric Solid Tumor Patients: A Systematic Review
Liesse, K., Harris, J. C., Chan, M. Q., Schmidt, M. L., & Chiu, B. (2018) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001118 · Cited by 51
Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance
Vasu, S., & Hundley, W. G. (2013) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-15-66 · Cited by 49
QT Prolongation and Oncology Drug Development
Fradley, M. G., & Moslehi, J. J. (2015) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2015.03.013 · Cited by 48
Self-citation
Statins and survival outcomes in patients with metastatic renal cell carcinoma
McKay, R. R., Lin, X., Albiges, L. K., Fay, A. P., Kaymakcalan, M. D., Mickey, S. S., Ghoroghchian, P. P., Bhatt, R. S., Kaffenberger, S. D., Simantov, R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.10.008 · Cited by 48
Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation
Viganego, F., Singh, R., & Fradley, M. G. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0730-0 · Cited by 45
Self-citation
Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN)
Pituskin, E., Haykowsky, M. J., McNeely, M. L., Mackey, J. R., Chua, N. S., & Paterson, D. I. (2016) · BMC Cancer · doi:10.1186/s12885-016-2761-8 · Cited by 45

Sorted by citations

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Lyon, A. R., López‐Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J. K., Boriani, G., Cardinale, D. M., Córdoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,457
Self-citation
Targeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Loibl, S., André, F., Bachelot, T., Barrios, C. H., Bergh, J. C. S., Burstein, H. J., Cardoso, M. J., Carey, L., Dawood, S. S., Mastro, L. D., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.11.016 · Cited by 1,135
Self-citation
Osteosarcoma
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
Herrmann, J., Lenihan, D. J., Armenian, S. H., Barac, A., Blaes, A. H., Cardinale, D. M., Carver, J. R., Dent, S. F., Ky, B., Lyon, A. R., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab674 · Cited by 699
Self-citation

See all 1,031

Authors: Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M. G., Orecchia, R., de Azambuja, E., Zamorano, J. L., Krone, R., Iakobishvili, Z., Carver, J., Armenian, S., Ky, B., Cardinale, D., Cipolla, C. M., Dent, S., & Jordan, K.
Affiliations: University of Milan (IT)
Washington University Medical Center (US)
University of South Florida (US)
Lahey Hospital and Medical Center (US)
Georgetown University (US)
University of Minnesota (US)
Mayo Clinic (US)
University of Kansas Medical Center (US)
Royal Brompton Hospital (GB)
Centre Hospitalier Universitaire de Liège (BE)
University of Chicago (US)
Vanderbilt University (US)
Stanford Medicine (US)
European Institute of Oncology (IT)
Hospital Universitario Ramón y Cajal (ES)
Washington University in St. Louis (US)
Tel Aviv University (IL)
Hospital of the University of Pennsylvania (US)
City Of Hope National Medical Center (US)
University of Pennsylvania (US)
Duke University (US)
Heidelberg University (DE)
ORCID: Curigliano, G.
Lenihan, D.
Fradley, M.
Ganatra, S.
Barac, A.
Blaes, A.
Porter, C.
Lyon, A.R.
Patel, A.
DeCara, J.
Mitchell, J.
Moslehi, J.
Witteles, R.
Orecchia, R.
Krone, R.
Iakobishvili, Z.
Carver, J.
Armenian, S.
Ky, B.
Cardinale, D.
Cipolla, C.M.
Dent, S.
Jordan, K.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2020-02
Volume: 31
Issue: 2
Pages: 171-190
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1016/j.annonc.2019.10.023
PMC: PMC8019325
OpenAlex: W2999536665
Cited by: 1,031
References: 221
Citations by year: 2026: 108 · 2025: 152 · 2024: 168 · 2023: 189 · 2022: 188 · 2021: 143 · 2020: 83
FWCI: 93.28
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 366 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
ORBi (University of Liège) (submittedVersion, other-oa)
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: HF
Genentech
Amgen
Servier
Pfizer
Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Keywords: cardio-oncology, cardiotoxicity, cancer therapy, heart failure, cardiovascular screening, cardiovascular monitoring, novel cancer therapies, cardiovascular disease in cancer patients
MeSH terms: Antineoplastic Agents, Heart Diseases, Humans, Medical Oncology, Neoplasms, Consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks